Award details

In vivo selection of bioprocessable biopharmaceuticals

Reference	BB/M01259X/1
Principal Investigator / Supervisor	Professor David Brockwell
Co-Investigators / Co-Supervisors	Professor Sheena Radford
Institution	University of Leeds
Department	Astbury Centre
Funding type	Research
Value (£)	113,379
Status	Completed
Type	Research Grant
Start date	01/06/2015
End date	31/05/2016
Duration	12 months

Abstract

The project is a collaboration between academics at the University of Leeds and stakeholders in biopharmaceutical production (MedImmune) and their biophysical characterisation (Avacta Group Plc). The objectives of this feasibility award application are: 1. To test whether an in vivo screen that reports on the aggregation of proteins/peptides in the periplasm of E. coli can be used (a) to predict bioprocessibility of candidate sequences of diverse protein platforms directly after affinity panning (b) to facilitate re-design of a previously identified candidate with high target affinity but poor biophysical properties and (c) to optimise formulation by quantifying the effects of excipients added to the bacterial growth medium. 2. To miniaturize and automate the screen to allow higher throughput in a 48-well format. Development of a screen that obviates the need to purify candidates and identifies failures early would reduce the time and cost of biologic development increasing the competitiveness of the industrial biotechnology sector in the UK.

Summary

Biopharmaceuticals (or biologics) are medicines that are made from biological materials, most usually proteins. The UK is a prominent stakeholder in this sector, which is growing in importance as biologics are often more specific to their target in the body and have fewer side effects. The development and production of biologics is, however, a labour and time intensive process. Many promising therapeutic proteins are never commercialised due to problems with self-association (aggregation). Failure of these 'candidate' therapeutics at a late stage of development is expensive to both industry and society as these therapies are usually indicated for serious life-threatening or life-limiting conditions. The aim of this project is to assess the ability of a screen developed by the applicants to identify candidate therapeutics at an early stage of development that are inherently resistant to aggregation. This would reduce the cost of development and reduce the failure rate of promising therapies for serious diseases.

Impact Summary

As described in proposal submitted to TSB

Committee	Not funded via Committee
Research Topics	Industrial Biotechnology, Microbiology, Pharmaceuticals, Structural Biology
Research Priority	X – Research Priority information not available
Research Initiative	Industrial Biotechnology Catalyst (IBCAT) [2014-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search